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Abstract
The heart is an exceedingly rare site of metastatic involvement in carcinoid tumors. Only nineteen
cases have been described in the literature over the past 30 years. We report here on a patient
who presented with progressive carcinoid syndrome despite surgical resection of her liver
metastases. She was found to have cardiac metastases on inidium-111-pentetreotide scintigraphy
and subsequently underwent external beam radiation to the heart resulting in symptomatic
palliation of her syndrome and objective radiographic response. To our knowledge, this is the first
reported case of metastatic cardiac carcinoid treated with external beam irradiation.
Case presentation
A 45 year-old woman with a history of metastatic carci-
noid disease presented to our institution with progressive
flushing and diarrhea.
She had been diagnosed with a carcinoid tumor 18
months earlier when an enlarged mesenteric lymph node
was discovered incidentally during laparoscopic gastric
bypass surgery. Pathologic evaluation demonstrated a
moderately differentiated neuroendocrine tumor. Labora-
tory studies revealed an elevation in 24 hour urine 5
hydroxyindoleacetic acid (5HIAA) of 37.4 mg (reference
range 1–6 mg) and an elevated serum serotonin of 1671
ng/ml (reference range 22–180 ng/ml). At the time of ini-
tial diagnosis, the patient denied any prior history of
flushing, diarrhea or wheezing.
Magnetic resonance imaging of the abdomen revealed
two hepatic masses, one in the dome of the liver measur-
ing 6.8 cm, and another in the posterior right hepatic lobe
measuring 2.2 cm. Indium-111-pentetreotide scintigra-
phy (OctreoScan™) revealed a focus of activity in the right
hepatic lobe, as well as two foci of intense activity in the
cardiac region (figure 1). A primary gastrointestinal or
bronchial tumor was not detected.
Depot octreotide therapy was initiated, and a series of
three laparoscopic hepatic radiofrequency ablations were
performed over the ensuing 6 months. Although this ther-
apy resulted in normalization of the 24-hour urine 5-
HIAA, serum serotonin remained elevated (539 ng/ml).
Moreover, the patient began developing progressive
diarrhea and intense facial flushing despite dose escala-
tion of depot octreotide from 30 mg to 60 mg every 4
weeks.
Repeat indium-111-pentetreotide scintigraphy twelve
months after initial diagnosis demonstrated resolution of
activity in the liver. However, persistent radiotracer uptake
was detected in the region of the myocardium. Echocardi-
ography was ordered to evaluate for the presence of car-
diac metastases. It demonstrated trace to mild tricuspid
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insufficiency and trace aortic insufficiency, but showed no
evidence of an intracardiac mass.
Magnetic resonance (MR) imaging of the chest was per-
formed using multiplanar breath-hold, electrocardio-
gram-gated HASTE (Half Fourier Single Shot Turbo Spin-
Echo) and electrocardiogram-gated, post-gadolinium T1-
weighted spin-echo images obtained on a 1.5-Tesla Sym-
phony MR scanner (Siemens Medical Systems, Malvern,
PA). The MR images demonstrated a 3.8 × 2.1 cm mildly
enhancing mass involving the free wall of the right ventri-
cle as well as a poorly-defined mass involving the mid
anterior left ventricular wall with extenstion to the apex.
(Figure 2). These masses correlated to sites of abnormal
radiotracer accumulation on indium-111-pentetreotide
scintigraphy (Figure 2 inset).
Consideration was given to surgical resection of the myo-
cardial metastases, however, the risk of malignant arrhyth-
mias was deemed prohibitive. Therefore, radiation
oncology was consulted for external beam irradiation. A
total of 45 Gray was delivered to the myocardium in 25
fractions using 3D-conformal technique (figure 3). The
patient's gross tumor volume (GTV) in both the right and
left ventricles was drawn on the planning CT scans that
had been taken with the patient in the supine position
with her arms immobilized over her head in a vac-lok bag.
The MRI images were used for aid in target volume delin-
eation. Four beams consisting of an anterior superior
oblique (ASO), anterior inferior oblique (AIO), left ante-
rior superior oblique (LASO), and a right anterior supe-
rior oblique (RASO) were planned to deliver 45 Gy to the
GTV + a 2 cm margin (figure 4). Dose volume histogram
(DVH) analysis showed that with this beam arrangement,
<40% of the heart received the prescribed dose of 45 Gy,
60% of the heart received 30 Gy, and 50% received 40 Gy.
30% of the total lung volume received 20 Gy. 100% of the
GTV received the prescription dose. Treatment was deliv-
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ered using 18 MV photons with 60 degree wedges on each
field. The therapy was complicated only by a brief episode
of chest pain and dyspnea without electrocardiographic
changes.
Repeat magnetic resonance imaging after completion of
radiation demonstrated a fifty percent bidimensional
reduction in the size of the right ventricular tumor (figure
5) associated with a substantial decrease in serum serot-
onin levels to 205 ng/ml. Six months after treatment, the
patient denied any chest pain, dyspnea or orthopnea and
reported a moderate improvement in her facial flushing
and diarrhea. Interferon α was added to octreotide ther-
apy for further management of her metastatic disease.
Discussion
Although right sided heart valve fibrosis and dysfunction
is a hallmark of carcinoid heart disease, myocardial
metastases from carcinoid tumors are distinctly uncom-
mon. Among 243 patients undergoing echocardiography
for evaluation for carcinoid heart disease, sonographic
evidence of cardiac tumor was observed in only 6 patients
(2%).[1] Another series of 132 patients undergoing
echocardiograms for evaluation of carcinoid heart disease
demonstrated a 4% rate of myocardial metastases.[2]
While echocardiography has been the primary technique
for identifying myocardial metastases from carcinoid
tumors, other methods have also been described in the lit-
erature. Puvaneswary et al. described the use of magnetic
resonance imaging for localization of cardiac metas-
tases[3], while Yeung et al. reviewed the use of 111Indium-
pentetreotide scintigraphy.[4] In this case, scintigraphy
demonstrated radiotracer uptake in the region of the heart
while MRI scans provided important anatomic informa-
tion enabling use of focused radiation therapy. Echocardi-
ography, however, failed to accurately identify the cardiac
tumors.
The location of cardiac metastases in prior reported cases
has included all chambers of the heart as well as pericar-
dium.[1,2,5,6] Two patients presented with malignant
arrhythmias, including one patient who developed fatal
bradycardia due to tumor infiltration of the atrioventricu-
lar node.[7] Carcinoid syndrome associated with eleva-
tion in urine 5HIAA has been documented in the majority
of cases described in the literature.
An interesting feature of this case was the persistence of
elevated serotonin along with progressive flushing and
diarrhea despite the successful resection of liver metas-
tases through radiofrequency ablation and normalization
of urine 5 hydroxyindolacetic acid (5HIAA). Since inacti-
vation of serotonin and its catabolism into 5HIAA occurs
partially in the lung, we hypothesize that the direct secre-
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Left ventricular mass before (5.a) and after (5.b) external beam irradiation.
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tion of serotonin into the systemic circulation by the left
ventricular metastasis may have resulted in exacerbation
of the carcinoid syndrome despite ablation of liver metas-
tases.
Surgical resection of cardiac metastases has been the ther-
apy of choice in the majority of carcinoid tumors
described in the literature.[1,2,4] A minority of cases were
treated with systemic chemotherapy.[5] The use of exter-
nal beam irradiation for control of cardiac metastases
from carcinoid tumors has not been described in the liter-
ature but there have been single institutional series report-
ing the effectiveness of radiation for other sites of
metastatic disease.
Schupak and Wallner reviewed 44 patients with meta-
static or unresectable carcinoid tumors who were treated
at Memorial Sloan-Kettering Cancer Center with radia-
tion.[8] The sites included in their series were epidural
space, brain, bone, and abdomen. Infield control follow-
ing radiotherapy was 77% for epidural sites and 78% for
bone sites. No patient with brain metastasis had progres-
sion of intracranial disease after radiation and 80% of
patients with abdominal disease achieved a complete or
partial response. The authors did not demonstrate a dose
response relationship and recommended 45–50 Gy in 4–
5 weeks for non-hepatic sites. Chakravarthy and Abrams
reported on 18 patients with metastatic or unresectable
carcinoid patients at Johns Hopkins.[9] In their series,
clinical improvement occurred in 87% of the sites irradi-
ated.
Cardiac effects of radiation have been evaluated in great
detail, with data derived largely from follow-up of long
term survivors of Hodgkin's disease. Current evidence has
shown that radiation to the heart can be associated with
pericardial disease, accelerated atherogenesis of the coro-
nary arteries, myocardial disease, valve defects, and pre-
disposition to conduction abnormalities.[10-13]
Conclusion
The heart is a rare site of involvement in metastatic carci-
noid tumors. Electrocardiogram-gated MRI may be a use-
ful imaging modality for anatomic delineation of the
tumor. Carcinoid tumors involving the myocardium can
produce substantial morbidity due to invasion of sensitive
cardiac structures and also due to secretion of serotonin
directly into the systemic circulation. When surgical resec-
tion is considered excessively risky, external beam irradia-
tion may be an effective option for palliation of
symptoms. The potential benefits need to be weighed
against the risks of pericardial, valvular and myocardial
toxicity as well as chronic atherogenesis.
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